{
    "organizations": [],
    "uuid": "b511bc328c7e6c5f90c7d3f238f4d745df83cbf8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-gets-us-approval-for-cose/brief-novartis-gets-u-s-approval-for-cosentyx-label-update-idUSASM000J2D",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis gets U.S. approval for Cosentyx label Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Novartis AG:\n* NOVARTIS RECEIVES FDA APPROVAL FOR COSENTYX® LABEL UPDATE TO INCLUDE MODERATE-TO-SEVERE SCALP PSORIASIS\n* NOVARTIS RECEIVES FDA APPROVAL FOR COSENTYX® LABEL UPDATE TO INCLUDE MODERATE-TO-SEVERE SCALP PSORIASIS\n* SAYS ‍THIS FOLLOWS A SIMILAR EUROPEAN LABEL UPDATE IN JUNE​ Further company coverage: (Reporting By Zurich newsroom)\n ",
    "published": "2018-02-08T14:28:00.000+02:00",
    "crawled": "2018-02-09T16:46:27.033+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novartis",
        "ag",
        "novartis",
        "receives",
        "fda",
        "approval",
        "label",
        "update",
        "include",
        "scalp",
        "psoriasis",
        "novartis",
        "receives",
        "fda",
        "approval",
        "label",
        "update",
        "include",
        "scalp",
        "psoriasis",
        "say",
        "follows",
        "similar",
        "european",
        "label",
        "update",
        "company",
        "coverage",
        "reporting",
        "zurich",
        "newsroom"
    ]
}